Article Sidebar
Views PDF: 107
EVALUATING THE SIDE EFFECTS OF TAFLUPROST 0.0015% IN PRIMARY OPEN ANGLE GLAUCOMA TREATMENT
Main Article Content
Abstract
Objectives: To evaluate the side effects of Tafluprost 0,0015%. Patients and Methods: A prospective descriptive study recruited 46 eyes of 28 POAG patients who were treated medically from February 2015 to September 2015. All side effects locally and systematically were analyxed at 1 week, 2 weeks, 1 month, 2 months, 3 months. Results: systematic side effects were not noted over 3 months of follow-up. Some local issues as eye irritation (6.2%), eye itching (3.1%), eye pain (3.1%) occurred at 2 weeks which responded well to treatment and disappeared at following check-up. Eye redness happened at 1 week but decreased over time. Eyelash elongation happened in only 2 eyes (4.3%) after 3 months of treatment. Mild and moderate eye dryness was seen in 50% and 25% of cases at 1 week that remained unchanged after 3 months (46,8% and 31.2%). The severe dry eye at 1 week was 6.2% and was improved to 0% after 3 months. Conclusion: Tafluprost 0.0015% was safe in POAG treatment without systematic side effects and with mild local side effects.
Article Details
Keywords
POAG, Tafluprost 0.0015%, side effects
References
2. Đỗ Thị Thái Hà (2002). Nghiên cứu một số đặc điểm dịch tễ học lâm sàng của bệnh nhân Glôcôm điều trị tại khoa Tổng hợp viện Mắt Đại Học y Hà Nội.
3. Yang Liu và Weiming Mao (2013). Tafluprost once daily for treatment of elevated intraocular pressure in patients with open-angle Clinical Ophthalmology, 7, 7–14.
4. Nguyễn Đỗ Thị Ngọc Hiên (2004). Góp phần nghiên cứu hiệu quả điều trị Glôcôm góc mở bằng thuốc Travatan, Trường đại học Y Hà nội.
5. Uusitalo H, Pillunat LE và Ropo A) (2010). Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double- masked Phase III study. Acta Ophthalmol, (88), 12–19.
6. Chabi A, Varma R và Tsai JC (2012). Randomized clinical trial of the efficacy and safety of preservative-free tafluprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol, (153), 1187–1196.
7. Takeshi Kumagami (2013). Comparison of corneal safety and intraocular pressure-lowering effect of tafluprost ophthalmic solution with other prostaglandin ophthalmic solutions. j Ocular Pharm Ther, 30 (4), 340-345.
8. HamacherT, Airaksinen J và Saarela V (2008). Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis. ActaOphthamol, 86 (24), 14-19.